Literature DB >> 25256676

Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.

Ross M Fasano1, Garrett S Booth, Megan Miles, Liping Du, Tatsuki Koyama, Emily Riehm Meier, Naomi L C Luban.   

Abstract

Sickle cell disease (SCD) patients are at increased risk of red blood cell (RBC) alloimmunization. Recipient inflammatory state at time of transfusion has been shown to regulate alloimmunization in murine models, but evidence is lacking in SCD patients. We retrospectively studied a cohort of alloimmunized SCD patients to determine the influence of pro-inflammatory SCD-related complications at time of transfusion on alloimmunization. For each transfusion, the presence of pro-inflammatory state, degree of RBC antigen matching, unit age, storage solution and alloantibody detection date were ascertained. Transfusion-associated pro-inflammatory events were compared between transfusions resulting and not resulting in new alloantibodies. Univariate analysis and multivariate logistic regression were performed. Fifty-two patients received 3166 pre-storage leuco-reduced transfusions of which 128 resulted in alloantibodies. Transfusions during inflammatory events were associated with increased alloantibody risk on univariate and multivariate analysis; acute chest syndrome and vaso-occlusive crisis showed strongest associations with alloimmunization. Increased antigen matching demonstrated a protective effect on alloimmunization (univariate and multivariate analysis). Although an association was seen between citrate-phosphate-dextrose (adenine) stored units and alloimmunization on univariate analysis, no effect was found on multivariate analysis. Identifying recipient pro-inflammatory states at time of transfusion that promote alloimmunization can impact RBC unit selection decisions for SCD patients at risk for alloimmunization.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  inflammation; red blood cell alloimmunization; sickle cell disease

Mesh:

Substances:

Year:  2014        PMID: 25256676     DOI: 10.1111/bjh.13123

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  49 in total

1.  Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice.

Authors:  David R Gibb; Jingchun Liu; Prabitha Natarajan; Manjula Santhanakrishnan; David J Madrid; Stephanie C Eisenbarth; James C Zimring; Akiko Iwasaki; Jeanne E Hendrickson
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

2.  Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Authors:  Dorothea Evers; Jaap Jan Zwaginga; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

Review 3.  Cellular immune responses in red blood cell alloimmunization.

Authors:  James C Zimring; Krystalyn E Hudson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Red blood cell storage lesion: causes and potential clinical consequences.

Authors:  Tatsuro Yoshida; Michel Prudent; Angelo D'alessandro
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

5.  A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease.

Authors:  Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard
Journal:  Blood Adv       Date:  2018-12-26

6.  Red blood cell storage duration is not associated with clinical outcomes for acute chest syndrome in children with sickle cell disease.

Authors:  Melanie E Fields; Monica L Hulbert; Ling Chen; Ari N Berlin; Ron Jackups; Philip C Spinella
Journal:  Transfusion       Date:  2015-05-30       Impact factor: 3.157

7.  Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.

Authors:  Sebastián Ortiz; Maria T Orero; Karla Javier; Carolina Villegas; Irene Luna; Pedro Pérez; Mónica Roig; María López; Sofía Costa; Félix Carbonell; Rosa Collado; David Ivars; Mariano Linares
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

Review 8.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

Review 9.  Genotyping in Sickle Cell Disease Patients: The French Strategy.

Authors:  Aline Floch; Christophe Tournamille; Btissam Chami; France Pirenne
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

Review 10.  Optimized Antigen-Matched in Sickle Cell Disease Patients: Chances and Challenges in Molecular Times - the Brazilian Way.

Authors:  Lilian Castilho; Carla Luana Dinardo
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.